Compare Smith & Nephew plc (SNN) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Smith & Nephew plc trades at $27.24 (market cap $11.10B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 6.5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 121 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| SNN | VCIT | |
|---|---|---|
Market Cap | $11.10B | $72.20B |
Volume | 1,051,703 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $37.17 | $84.82 |
52-Week Low | $26.42 | $77.98 |
Typical Hold Time | 121 Days | 62 Days |
Enterprise Value | $14.13B | — |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
VCIT (Vanguard Intermediate-Term Corporate Bond ETF) trades at $78.48, up 0.27% with a bearish technical signal from moving averages. The ETF offers a 4.8% yield and 5.1% yield-to-maturity with a 6-year duration, positioning it as a core fixed-income holding. Recent institutional buying includes Engineers Gate Manager's $1.27 million purchase and HB Wealth Management increasing holdings by 242.9%.
VCIT presents a compelling risk-return profile for income investors seeking corporate bond exposure with low costs. The 0.03% expense ratio provides cost efficiency versus competitors. Risks include interest rate sensitivity and corporate credit quality concerns. Technical indicators suggest near-term consolidation around $78 support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
